Brief: Mundipharma And Cidara Therapeutics Receive Positive CHMP Opinion For Rezafungin For The Treatment Of Invasive Candidiasis In Adults
13/10/2023 17:31
Oct 13 (Reuters) - Cidara Therapeutics Inc CDTX.O :
* MUNDIPHARMA AND CIDARA THERAPEUTICS RECEIVE POSITIVE CHMP
OPINION FOR REZAFUNGIN FOR THE TREATMENT OF INVASIVE CANDIDIASIS
IN ADULTS1
Source text for Eikon: ID:nBw8Gkr10a
Further company coverage: CDTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade